Problem of resistant arterial hypertension in the family doctor practice.

Prof. O.M. Korzh. Kharkov Medical Academy of Postgraduate Education, Department of General Practice-Family Medicine.

Resistant arterial hypertension is diagnosed when three antihypertensives assignment does not result in achieving target blood pressure, which for most patients is the level below 140/90 mm Hg, wherein one of the medicaments must be diuretic and all drugs must be assigned to optimal or maximum tolerated doses. Although arbitrary number required to control blood pressure drugs, the determination is very useful from the point of view of both the clinician and researcher, since it helps to identify the phenotype of resistance to a wide antihypertensive treatment and diagnostic determining tactics, such as testing or causes of secondary hypertension selection treatment. Since patients with resistant arterial hypertension have a higher probability of detection of diseases, leading to the development of secondary hypertension. These include sleep apnea, kidney disease, renal artery stenosis, primary aldosteronism. Despite the high prevalence of resistant arterial hypertension, the lack of blood pressure control is often associated with an inadequate selection of antihypertensive therapy, blood pressure misjudgment or failure of patients to medical recommendations. Therefore, before carrying out diagnostic measures necessary to consistently assess the adequacy of patients receiving therapy that inherent in the definition of resistant arterial hypertension and exclude pseudoresistance.

Кey Words: resistant arterial hypertension, diagnostics, treatment.

Korzh OM. [Problem of resistant arterial hypertension in the family doctor practice]. Shidnoevr. z. vnutr. simejnoi med. 2015;2:26-31. Russian.

http://dx.doi.org/10.15407/internalmed2015.02.026

Download.PDF

1. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD [American Heart Association Scientific Statement on Resistant Hypertension: diagnosis, evaluation, and treatment]. Hypertension. 2008; 51: 1403—1419. English http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.189141

2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM [Heart disease and stroke statistics—2011 update: a report from the American Heart Association]. Circulation. 2011; 123: 118—129. English http://dx.doi.org/10.1161/CIR.0b013e3182009701

3. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL. [Incidence and prognosis of resistant hypertension in hypertensive patients]. Circulation. 2012; 125: 1635—1642. English http://dx.doi.org/10.1161/CIRCULATIONAHA.111.068064

4. Florczak E, Szwench E, Siliwinski P, Bielen P, Klisiewicz A, Michalowska I [Clinical characteristics of patients with resistant hypertension]. J Human Hypertens. 2013; 27: 678—685. English http://dx.doi.org/10.1038/jhh.2013.32

5. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM [Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension]. J Clin Sleep Med. 2010; 6: 363—368. English

6. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C [Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patient]. J Clin Endocrinol Metab. 2008; 93: 2566—2571. English http://dx.doi.org/10.1210/jc.2008-0251

7. Grigoryan L, Pavlik VN, Hyman DJ. [Characteristics, drug combinations and dosages for primary care patients with uncontrolled ambulatory blood pressure and high medication adherence]. J Am Soc Hypertens. 2013; 7: 471—476. English http://dx.doi.org/10.1016/j.jash.2013.06.004

8. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JG, Phillips BB, Zimmerman MB. [Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure]. Hypertension. 2006; 47: 352—358. English http://dx.doi.org/10.1161/01.HYP.0000203309.07140.d3

9. Chapman N, Dobson J, Wilson S, Dahllof B, Sever PS, Wedel H. [Effect of spironolactone on blood pressure in subjects with resistant hypertension]. Hypertension. 2007; 49: 839—845. English http://dx.doi.org/10.1161/01.HYP.0000259805.18468.8c

10. Calhoun DA, White WB. [Effectiveness of the selective aldosterone antagonist eplerenone in treating resistant hypertension]. J Am Soc Hypertens. 2008; 2: 462—468. English http://dx.doi.org/10.1016/j.jash.2008.05.005

11. Sierra DA, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P [Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring]. Hypertension. 2011; 57: 898—902. English http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.168948

12. Muxfeldt ES, Fiszman R, Souza DF, Viegas B, Oliveira FC, Salles GF. [Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension]. Hypertension. 2012; 59: 384—389. English http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.185405

13. Daugherty SL, Powers JD, Magid DJ, Masoudi FA, Margolis KL, O’Connor PJ. [The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension]. Hypertension. 2012; 60: 303—309. English http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.192096

14. Fagard RH, Cornelissen VA. [Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis]. J Hypertens. 2007; 25: 2193—2198. English http://dx.doi.org/10.1097/HJH.0b013e3282ef6185

15. Fagard RH, Celis H, Thijs L. [Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension]. Hypertension. 2008; 51: 55—61. English http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.100727

16. Ernst ME, Carter BL, Goerdt CJ. [Comparative antihypertensive effect of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure]. Hypertension. 2006; 47: 352—358. English http://dx.doi.org/10.1161/01.HYP.0000203309.07140.d3

17. Nishizaka MK, Zaman MA, Calhoun DA. [Efficacy of low-dose spironolactone in subjects with resistant hypertension]. Am J Hypertens. 2003; 16: 925—930. English http://dx.doi.org/10.1016/S0895-7061(03)01032-X

18. Schlaich MP, Krum H, Sobotka PA. [Renal denervation and hypertension]. Am J Hypertens. 2011; 24: 635—642. English http://dx.doi.org/10.1038/ajh.2011.35

19. [Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomized controlled trial]. Lancet. 2010; 376: 1903—1909. English

20. Scheffers IM, Kroon AA, Schmidli J. [Novel baroreflex activation therapy in resistant hypertension]. J Am Coll Cardiol. 2010; 56: 1254—1258. English http://dx.doi.org/10.1016/j.jacc.2010.03.089

21. Bisognano JD, Bakris G, Nadim MK. [Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebocontrolled]. J Am Coll Cardiol. 2011; 58: 765—773. English http://dx.doi.org/10.1016/j.jacc.2011.06.008

22. Donazzan L, Mahfoud F, Ewen S. [Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension]. Clin Res Cardiol. 2015; 23: 47—54. English

23. Ewen S, Dörr O, Ukena C. [Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension] J Hypertens. 2015; 45: 1116—1121. English

24. Vongpatanasin W. [Resistant hypertension: a review of diagnosis and management]. JAMA. 2014; 311: 2216 — 2224. English http://dx.doi.org/10.1001/jama.2014.5180

25. Denolle T, Chamontin B, Doll G. [Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology]. Presse Med. 2014; 12: 1325 — 1331. English http://dx.doi.org/10.1016/j.lpm.2014.07.016

26. Ripp TM, Mordovin VF, Pekarskiy SE. [Predictors of Renal Denervation Efficacy in the Treatment of Resistant Hypertension]. Curr Hypertens Rep. 2015; 17: 90—94. English http://dx.doi.org/10.1007/s11906-015-0603-8

27. Patel P, Gupta PK, White CM. [Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation]. J. Hum. Hypertens. 2015; 25: 82—86. English

28. Tomaszewski M, White C, Patel P. [High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis]. Heart. 2014; 100: 855—861. English http://dx.doi.org/10.1136/heartjnl-2013-305063

29. Huynh K. [Hypertension: PATHWAY to improving the treatment of drug-resistant hypertension]. Nat Rev Cardiol. 2015; 39: 62—68. English